Library

Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C [printed text] / Sophie Gerkens , Author ; Nancy Thiry, Author ; Frank Hulstaert, Author ; Jo Robays, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2016 . - 144 p. : ill., ; A4. - (KCE Reports. Health Technology Assessment (HTA); 276C) .
ISSN : D/2016/10.273/88 : € 0,00
Study 2015-08
Languages : English (eng)

Descriptors:	Indexation 2015-08 ; Antiviral Agents ; Cost-Benefit Analysis ; Hepatitis C ; R276 Classification WC 536 Human viral hepatitis
Contents note:	SCIENTIFIC REPORT 14 -- 1 INTRODUCTION .14 -- 1.1 BACKGROUND 14 -- 1.1.1 Transmission 14 -- 1.1.2 Hepatitis C in Belgium 15 -- 1.1.3 Treatments 16 -- 1.2 OBJECTIVE OF THIS REPORT AND RESEARCH QUESTIONS 17 -- 2 REVIEW OF THE PUBLISHED ECONOMIC EVALUATIONS 18 2.1 INTRODUCTION .18 -- 2.2 METHODS 18 2.2.1 Inclusion and exclusion criteria .18 -- 2.2.2 Search strategy .19 2.2.3 Selection procedure 19 2.2.4 Coverage of the reviews 21 -- 2.3 CLASSIFICATION OF THE ECONOMIC EVALUATIONS 21 -- 2.3.1 Early publications based on emerging and weak evidence 21 -- 2.3.2 Pegylated interferon as an intervention 21 -- 2.3.3 Disease progression after sustained viral response 22 -- 2.3.4 Selected economic evaluations 22 -- 2.4 OVERVIEW OF THE SELECTED ECONOMIC EVALUATIONS 23 -- 2.4.1 Country and study design 23 -- 2.4.2 Perspective .23 -- 2.4.3 Time horizon and discount rate .23 -- 2.4.4 Targeted patient group 23 -- 2.4.5 Intervention and comparators 23 -- 2.4.6 Assumptions used in modelling the HCV natural history .24 2.4.7 Non-liver mortality 25 -- 2.4.8 Quality of life 25 -- 2.5 MAIN RESULTS OF THE ECONOMIC EVALUATIONS 34 -- 2.5.1 Genotype 1 34 -- 2.5.2 Genotype 2 35 -- 2.5.3 Genotype 3 35 -- 2.5.4 Genotype 4 35 -- 2.6 SENSITIVITY AND SUBGROUP ANALYSES .35 -- 2.6.1 Sensitivity analyses .35 -- 2.6.2 Subgroup analyses .35 -- 2.7 DISCUSSION 41 -- 2.7.1 Summary of the results .41 -- 2.7.2 General conclusion .42 -- 3 THE COST-EFFECTIVENESS AND BUDGET IMPACT OF TREATMENT STRATEGIES FOR HEPATITIS C IN BELGIUM 43 -- 3.1 INTRODUCTION .43 -- 3.2 METHODS 43 -- 3.2.1 Design and analytic technique 43 -- 3.2.2 Perspective .44 -- 3.2.3 Time window and discounting 44 -- 3.2.4 Target population .44 -- 3.2.5 Intervention and comparator 45 -- 3.2.6 Model structure and basic assumptions 45 -- 3.2.7 Transition probabilities 48 -- 3.2.8 Performance of non-invasive liver tests 50 -- 3.2.9 Effectiveness of antiviral treatment .52 -- 3.2.10 Disease management, diagnostic tests and treatment costs 53 -- 3.2.11 Utilities 59 -- 3.2.12 Uncertainty 63 -- 3.2.13 Validation of the model 66 -- 3.3 RESULTS 66 -- 3.3.1 Cost-effectiveness analysis.66 -- 3.3.2 Budget impact analysis .72 -- 4 DISCUSSION AND CONCLUSION 80 --  APPPENDICES 83 -- APPENDIX 1. SCENARIO ANALYSES .83 -- APPENDIX 1.1. KCE REPORTS 157 ANTIVIRAL TREATMENT - ANNUAL TRANSITION PROBABILITIES BETWEEN FIBROSIS STAGES103 83 -- APPENDIX 1.2. TABLES OF THE SCENARIO ANALYSES FOR THE COST-EFFECTIVENESS ANALYSES 86 -- REFERENCES . 137
Link for e-copy:	http://doi.org/10.57598/R276C
Format of e-copy:	PDF (825 Kb)
Record link:	https://kce.docressources.info/index.php?lvl=notice_display&id=3943